Abstract
Background: Cure rates for eradication of Helicobacter pylori appear to be decreasing, thus more effective therapies must be identified. Aim: To evaluate the efficacy of bovine lactoferrin in the treatment of H. pylori infection. Methods: In a multicentred prospective study, 402 (mean age 52.4, range 19-84 years) H. pylori-positive patients were assigned to one of three regimens: group A - esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. for 7 days; group B - lactoferrin 200 mg b.d. for 7 days followed by the same schedule of group A; group C - esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. plus lactoferrin 200 mg b.d. for 7 days. Results: Of the 402 patients, 389 completed the study. Six patients were discontinued due to side effects, one patient in group B died and six patients were lost to follow up. The eradication rate (intention-to-treat analysis) was 77% in group A (105/136), 73% in group B (97/132) and 90% in group C (120/134) (χ2-test P <0.01). The incidence of side effects was 9.5% in group A, 9% in group B and 8.2% in group C (χ2-test P = 0.1). Conclusion: This study demonstrates that bovine lactoferrin is an effective adjuvant to 7-day triple therapy for eradication of H. pylori infection.
| Original language | English |
|---|---|
| Pages (from-to) | 1235-1240 |
| Number of pages | 6 |
| Journal | Alimentary Pharmacology and Therapeutics |
| Volume | 23 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Apr 2006 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Bovine lactoferrin for Helicobacter pylori eradication : An open, randomized, multicentre study. / Di Mario, F.; Aragona, G.; Dal Bó, N.; Cavallaro, L.; Marcon, V.; Olivieri, P.; Benedetti, E.; Orzès, N.; Marin, R.; Tafner, G.; Chilovi, F.; De Bastiani, R.; Fedrizzi, F.; Franceschi, M.; Salvat, M. H.; Monica, F.; Piazzi, L.; Valiante, F.; Vecchiati, U.; Cavestro, G. M.; Comparato, G.; Iori, V.; Maino, M.; Leandro, G.; Pilotto, A.; Rugge, M.; Franzè, A.
In: Alimentary Pharmacology and Therapeutics, Vol. 23, No. 8, 04.2006, p. 1235-1240.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bovine lactoferrin for Helicobacter pylori eradication
T2 - An open, randomized, multicentre study
AU - Di Mario, F.
AU - Aragona, G.
AU - Dal Bó, N.
AU - Cavallaro, L.
AU - Marcon, V.
AU - Olivieri, P.
AU - Benedetti, E.
AU - Orzès, N.
AU - Marin, R.
AU - Tafner, G.
AU - Chilovi, F.
AU - De Bastiani, R.
AU - Fedrizzi, F.
AU - Franceschi, M.
AU - Salvat, M. H.
AU - Monica, F.
AU - Piazzi, L.
AU - Valiante, F.
AU - Vecchiati, U.
AU - Cavestro, G. M.
AU - Comparato, G.
AU - Iori, V.
AU - Maino, M.
AU - Leandro, G.
AU - Pilotto, A.
AU - Rugge, M.
AU - Franzè, A.
PY - 2006/4
Y1 - 2006/4
N2 - Background: Cure rates for eradication of Helicobacter pylori appear to be decreasing, thus more effective therapies must be identified. Aim: To evaluate the efficacy of bovine lactoferrin in the treatment of H. pylori infection. Methods: In a multicentred prospective study, 402 (mean age 52.4, range 19-84 years) H. pylori-positive patients were assigned to one of three regimens: group A - esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. for 7 days; group B - lactoferrin 200 mg b.d. for 7 days followed by the same schedule of group A; group C - esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. plus lactoferrin 200 mg b.d. for 7 days. Results: Of the 402 patients, 389 completed the study. Six patients were discontinued due to side effects, one patient in group B died and six patients were lost to follow up. The eradication rate (intention-to-treat analysis) was 77% in group A (105/136), 73% in group B (97/132) and 90% in group C (120/134) (χ2-test P <0.01). The incidence of side effects was 9.5% in group A, 9% in group B and 8.2% in group C (χ2-test P = 0.1). Conclusion: This study demonstrates that bovine lactoferrin is an effective adjuvant to 7-day triple therapy for eradication of H. pylori infection.
AB - Background: Cure rates for eradication of Helicobacter pylori appear to be decreasing, thus more effective therapies must be identified. Aim: To evaluate the efficacy of bovine lactoferrin in the treatment of H. pylori infection. Methods: In a multicentred prospective study, 402 (mean age 52.4, range 19-84 years) H. pylori-positive patients were assigned to one of three regimens: group A - esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. for 7 days; group B - lactoferrin 200 mg b.d. for 7 days followed by the same schedule of group A; group C - esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. plus lactoferrin 200 mg b.d. for 7 days. Results: Of the 402 patients, 389 completed the study. Six patients were discontinued due to side effects, one patient in group B died and six patients were lost to follow up. The eradication rate (intention-to-treat analysis) was 77% in group A (105/136), 73% in group B (97/132) and 90% in group C (120/134) (χ2-test P <0.01). The incidence of side effects was 9.5% in group A, 9% in group B and 8.2% in group C (χ2-test P = 0.1). Conclusion: This study demonstrates that bovine lactoferrin is an effective adjuvant to 7-day triple therapy for eradication of H. pylori infection.
UR - http://www.scopus.com/inward/record.url?scp=33646875068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646875068&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2036.2006.02851.x
DO - 10.1111/j.1365-2036.2006.02851.x
M3 - Article
C2 - 16611285
AN - SCOPUS:33646875068
VL - 23
SP - 1235
EP - 1240
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 8
ER -